What do systematic reviews say?

Summary of findings ‐ auto‐hypnosis (self‐hypnosis) vs control

The review found no eligible studies for this question.

• Psychological interventions for people with hemophilia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 612 participants
  Very low

Deferasirox vs deferiprone (DFO)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Deferasirox vs deferiprone (DFO)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 390 participants
  Low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  1.54 [0.44, 5.39]
  1 study · 390 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

It is very uncertain whether summary of findings: Comparison 3 ‐ deferiprone (DFP) changes total SAEs compared with deferasirox (DFX) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 0.95 [0.46, 1.96]
  1 study · 390 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

Summary of findings: Comparison 3 ‐ deferiprone (DFP) showed no clear difference in all‐cause mortality (n/N) compared with deferasirox (DFX) (low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RD 0
  1 study · 390 participants
  Low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

It is very uncertain whether summary of findings: Comparison 1 ‐ deferiprone (DFP) changes total reported SAEs (from therapy, disease, non‐adherence) compared with deferoxamine (DFO) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 1.43 [0.83, 2.46]
  1 study · 228 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

It is very uncertain whether summary of findings: Comparison 1 ‐ deferiprone (DFP) changes all‐cause mortality compared with deferoxamine (DFO) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 0.47 [0.18, 1.21]
  3 studies · 376 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Very low

Deferasirox vs deferiprone (DFO)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 452 participants
  Very low

Deferasirox vs deferiprone (DFO)

It is very uncertain whether summary of findings: Comparison 2 ‐ deferasirox (DFX) changes SAEs Thalassaemia‐related SAEs compared with deferiprone (DFO) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 0.95 [0.41, 2.17]
  2 studies · 247 participants
  Very low

Deferasirox vs deferiprone (DFO)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 195 participants
  Very low

Deferasirox vs deferiprone (DFO)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  0.96 [0.06, 15.42]
  2 studies · 240 participants
  Very low

Medication management vs usual care

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Medication management vs usual care

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found